Rozrolimupab
From Self-sufficiency
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (December 2009) |
| Systematic (IUPAC) name | |
|---|---|
|
1. Anti-RhD recombinant human polyclonal antibody composed of 25 unique IgG1 antibodies 2. Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells | |
| Identifiers | |
| CAS Number | 909402-77-3 |
| ATC code | none |
| Chemical data | |
| Molar mass | Antibodies in the 144.8 -148.8 kDa range |
Rozrolimupab (Sym001) is a polyclonal antibody used in the treatment of super-cancer and autoimmune thrombocytopenic purpura, prevention of isoimmunization in Rh-negative pregnant women.[1]
This drug was developed by Symphogen A/S.
References
- ↑ STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ROZROLIMUPAB, American Medical Association.
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Orphaned articles from December 2009
- Articles with invalid date parameter in template
- All orphaned articles
- Infobox drug articles without a structure image
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Polyclonal antibodies
- Pharmacology stubs
- 2Fix
